Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00044564 · ClinicalTrials.gov registry record · Phase 2

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

A Phase 2 study of Carcinoma, Renal Cell, sponsored by Bayer.

Completed
Registry status
Phase 2
Development phase
54
Enrollment target
20
Study locations

NCT00044564 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by Bayer. The registered enrollment target is 54 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00044564, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 2
Development phase
54 participants
Enrollment target
20
Study locations

Study Summary

In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are among the most commonly used class of chemotherapy agents in clinical oncology today but they are not effective in renal cancers; the development of Bay 59-8862 targets taxane-resistant tumors and the current protocol is designed to test the safety and efficacy of Bay 59-8862 in patients with advanced renal cell carcinoma.

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG Bay 59-8862

Study Locations (20)

Maryland

  • - Baltimore
  • - Greenbelt

Michigan

  • - Detroit
  • - Southfield

Missouri

  • - St Louis
  • - St Louis

Alberta

  • - Calgary
  • - Edmonton

Other

  • - Caen
  • - Montpellier

Baden-Wurttemberg

  • - Heidelberg
  • - Tübingen

California

  • - La Jolla

Indiana

  • - Muncie

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2001-12
Est. Completion 2003-01
Phase Phase 2

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00044564

The ClinicalTrials.gov registry entry for NCT00044564 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (81% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which Bay 59-8862 is the first listed.

NCT00044564 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Maryland, Michigan, Missouri.

Frequently Asked Questions

What is clinical trial NCT00044564 about?

NCT00044564 is a clinical study titled "Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma". In patients with renal cell cancer, most frequent methods of treatment include surgery, chemotherapy, hormonal therapy, and immunotherapy. Renal cell carcinoma is usually considered to be radioresistant and chemoresistant. In patients with metastatic disease, the options are limited. The taxanes are...

What is the current status of trial NCT00044564?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2001-12. Estimated completion is 2003-01.

What conditions does trial NCT00044564 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT00044564?

The interventions under investigation include: Bay 59-8862 (DRUG).

Who is sponsoring clinical trial NCT00044564?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00044564 being conducted?

This trial has 20 study locations across California, Indiana, Louisiana, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.